Uncomplicated Urinary Tract Infection Market
The Uncomplicated Urinary Tract Infection market report provides current treatment practices, emerging drugs, Uncomplicated Urinary Tract Infection market share of the individual therapies, current and forecasted Uncomplicated Urinary Tract Infection market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Uncomplicated Urinary Tract Infection treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Uncomplicated Urinary Tract Infection Market Outlook
The Uncomplicated Urinary Tract Infection market size in the 7MM is expected to change during the study period 2018–2030. The therapeutic market of Uncomplicated Urinary Tract Infection in the seven major markets is expected to increase during the study period (2018–2030) with a CAGR of 10.8%. According to the estimates, the highest market size of Uncomplicated Urinary Tract Infection is found in the United States followed by Japan.
The United States Market Outlook
The total market size of Uncomplicated Urinary Tract Infection therapies in the United States is expected to increase with a CAGR of 11.6% in the study period (2018–2030).
EU-5 Countries: Market Outlook
The total market size of Uncomplicated Urinary Tract Infection therapies in EU-5 countries is expected to increase with a CAGR of 10.5% in the study period (2018–2030).
Japan Market Outlook
The total market size of Uncomplicated Urinary Tract Infection therapies in Japan is expected to increase with a CAGR of 7.1% in the study period (2018–2030).
Uncomplicated Urinary Tract Infection Pipeline Development Activities
The drugs which are in pipeline include:
- GSK2140944/Gepotidacin (GlaxoSmithKline)
- Sulopenem Etzadroxil – Probenecid (Iterum Therapeutics)
- Uromune/MV140 (Inmunotek)
- ExPEC Vaccine/ExPEC10V and ExPEC4V (Janssen Pharmaceuticals)
- GSK3882347 (GlaxoSmithKline/Fimbrion Therapeutics)
Table of contents
1. Key Insights
2. Report Introduction
3. Uncomplicated Urinary Tract Infection Market Overview at a Glance
3.1. Market Share (%) Distribution of Uncomplicated Urinary Tract Infection in 2018
3.2. Market Share (%) Distribution of Uncomplicated Urinary Tract Infection in 2030
4. Executive Summary of Uncomplicated Urinary Tract Infection (uUTI)
4.1. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Types of UTI
6.3. Signs and Symptoms of Uncomplicated UTI
6.4. Risk Factors and Causes of Uncomplicated UTI
6.5. Pathogenesis of UTI
6.6. Complications of UTI
7. Diagnosis of Uncomplicated UTI
7.1. Diagnostic algorithm
7.2. Clinical Examination
7.3. Lab Tests
7.4. Imaging and other tests
7.4.1. Cystoscopy
7.4.2. Ureteroscopy
7.5. Differential diagnosis
8. Prevention of UTI
9. Diagnostic Guidelines
9.1. European Association of Urology (EAU) Urological Infections Diagnostic Guidelines
9.2. American Urological Association (AUA) Guidelines
9.3. Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)
10. Current Treatment Practices of Uncomplicated UTI
10.1. Treatment Algorithm
10.2. Antibiotic therapy
10.2.1. Uncomplicated cystitis
10.2.2. Uncomplicated pyelonephritis
10.2.3. Recurrent UTI
10.3. Antibiotic prophylaxis
11. Treatment Guidelines
11.1. American Urological Association (AUA) Guidelines
11.2. European Association of Urology (EAU) Urological Infections Treatment Guidelines
11.3. Comparison of AUA/CUA/SUFU and EAU Guidelines
11.4. National Institute for Health and Care Excellence (NICE) Guidelines
11.5. Infectious Diseases Society of America (IDSA), in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) Guidelines
11.6. Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)
11.7. NICE – Antimicrobial prescribing strategy for lower UTI (also called cystitis)
12. Epidemiology and Patient Population
12.1. Key Findings
12.2. Epidemiology of Uncomplicated Urinary Tract Infection (uUTI)
12.3. Epidemiology Scenario
12.3.1. Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection
12.3.2. Total Diagnosed Cases of Uncomplicated Urinary Tract Infection
12.3.3. Total Age-specific Cases of Uncomplicated Urinary Tract Infection
12.3.4. Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection
12.3.5. Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection
13. Patient Journey
14. Key Endpoints in Uncomplicated UTI Clinical Trials
15. Emerging Therapies
15.1. GSK2140944 (Gepotidacin): GlaxoSmithKline
15.1.1. Product Description
15.1.2. Other Developmental Activities
15.1.3. Clinical Development
15.1.4. Safety and Efficacy
15.2. Sulopenem Etzadroxil – Probenecid: Iterum Therapeutics
15.2.1. Product Description
15.2.2. Other Developmental Activities
15.2.3. Clinical Development
15.2.4. Safety and Efficacy
15.3. Uromune (MV140): Inmunotek
15.3.1. Product Description
15.3.2. Other Developmental Activities
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. ExPEC Vaccine (ExPEC10V and ExPEC4V): Janssen Pharmaceuticals
15.4.1. Product Description
15.4.2. Other Developmental Activities
15.4.3. Clinical Development
15.5. GSK3882347: GlaxoSmithKline/Fimbrion Therapeutics
15.5.1. Product Description
15.5.2. Other Developmental Activities
15.5.3. Clinical Development
16. Uncomplicated Urinary Tract Infection: 7 Major Market Analysis
16.1. Key Findings
16.2. Market Outlook
16.3. Market Size of Uncomplicated Urinary Tract Infection
16.3.1. Total Market Size of Uncomplicated Urinary Tract Infection
16.3.2. Market Size of Uncomplicated Urinary Tract Infection by Therapies
17. Market Access and Reimbursement
17.1. Key HTA decisions for Uncomplicated UTI
17.2. Reimbursement
17.3. Patient Access Programs
18. Market Drivers
19. Market Barriers
20. SWOT Analysis
21. Unmet Needs
22. Appendix
22.1. Bibliography
22.2. Report Methodology
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
Request for sample pages @ market size of Uncomplicated Urinary Tract Infection
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/